Emerging therapies for hepatitis C virus

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

(2009) S. T. Shi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins

(2009) Heshaam M. Mir et al.   Clinics in Liver Disease

HCV genetic variability: from quasispecies evolution to genotype classification

(2009) Claudio Argentini et al.   Future Microbiology

Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

(2009) Gary L. Davis et al.   GASTROENTEROLOGY

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial

(2008) Eugene Schiff et al.   GASTROENTEROLOGY

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

(2008) Paul J. Pockros et al.   HEPATOLOGY

High relapse rate seen at week 72 for patients treated with R1626 combination therapy

(2008) Paul Pockros et al.   HEPATOLOGY

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS

(2008) J. Lalezari et al.   JOURNAL OF HEPATOLOGY